

Page 4, line 12, replace "labelled" with -labeled-;
Page 4, line 13, after "(AHWSGHCL)", insert -SEQ ID NO: 1-;
Page 4, line 17, insert a comma after "of";
Page 4, line 18, insert a comma after "respectively";
Page 4, line 19, replace "labelled" with -labeled-;
Page 4, lines 22-23, replace "of reducing" with -to reduce-;
Page 4, line 25, replace "labelled" with -labeled-;
Page 4, line 27, replace "labelled" with -labeled-;
Page 4, line 28, replace "In cases like this it" with -It-;
Page 4, line 29, replace "occurs" with -occur-;
Page 4, line 32, replace "It goes without saying that the" with -The-;
Page 5, lines 13-14, replace "Applicant considers the possibility that migraine is also"

with -Migraines may also be-;

Page 5, line 16, replace "an advantageous" with -a preferred-;
Page 8, line 4, replace "foetal" with -fetal-;
Page 8, line 5, replace "FTIC-labelled" with -FITC-labeled-;
Page 8, line 11, replace "unlabelled" with -unlabeled-;
Page 8, line 20, replace "min." with -minutes-;
Page 10, line 21, replace "sensitisation" with -sensitization-; and
Page 12, line 11, replace "Fig." with -FIG.-.

IN THE CLAIMS:

Mark C 3
Q1
3. (Amended) The compound of claim 1 [or 2], wherein the compound reduces the binding between the peptide and the free light chain of immunoglobulin by at least 10%, preferably by at least 25%, more preferably by at least 50%, even more preferably by at least 75%, and most preferably by 90%].

4. (Amended) The compound of claim 2 [or 3], wherein the compound is a peptidomimeticum.